Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693622 · ClinicalTrials.gov registry record
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
A clinical trial of Barrett Esophagus and Gastroesophageal Reflux Disease, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 556
- Enrollment target
- 1
- Study location
NCT06693622: Recruiting study of Barrett Esophagus and Gastroesophageal Reflux Disease, sponsored by University of Colorado, Denver.
NCT06693622 is a study of Barrett Esophagus and Gastroesophageal Reflux Disease that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 556 participants, below the 3,548-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693622, a study of Barrett Esophagus and Gastroesophageal Reflux Disease, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 556 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decrease the number of people who die from esophageal cancer.
Primary Outcome
A discrete choice-based conjoint analysis survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms will be used to determine the relative importance of BE/EAC screening test characteristics and patient priorities. Survey data will be reported in aggregate and factors and choices will be analyzed using the Fisher Exact and Mann-Whitney rank-sum tests. This approach will elicit the ov
Conditions Studied
Interventions
- BEHAVIORAL Patient survey
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2029-03-01 |
What NCT06693622 shows while recruiting
NCT06693622 is an observational study that tracks outcomes without assigning an intervention. The registered 556 participants enrollment target is mid-sized for trials with a published cap, below the 3,548-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which Patient survey is the first listed.
NCT06693622 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06693622 about?
NCT06693622 is a clinical study titled "Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests". This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decr...
What is the current status of trial NCT06693622?
This trial is currently recruiting. The enrollment target is 556 participants. The study started on 2024-11-01. Estimated completion is 2029-03-01.
What conditions does trial NCT06693622 study?
This clinical trial studies the following conditions: Barrett Esophagus, Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT06693622?
The interventions under investigation include: Patient survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT06693622?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693622 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693622's enrollment target sits among peer trials
556 12th of 32 higher than 21 of 32 other Barrett Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RECRUITING
-
Longitudinal Oral Microbiome Sampling for BE
RECRUITING
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI